Majeed Syndrome: A Review of the Clinical, Genetic and Immunologic Features

• Main Authors: Polly J. Ferguson, Hatem El-Shanti
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: Biomolecules
• Subjects: majeed syndrome; LPIN2; LIPIN2; chronic non-bacterial osteomyelitis; chronic recurrent multifocal osteomyelitis; autoinflammatory
• Online Access: https://www.mdpi.com/2218-273X/11/3/367

Majeed syndrome is a multi-system inflammatory disorder affecting humans that presents with chronic multifocal osteomyelitis, congenital dyserythropoietic anemia, with or without a neutrophilic dermatosis. The disease is an autosomal recessive disorder caused by mutations in <i>LPIN2</i>, the gene encoding the phosphatidic acid phosphatase LIPIN2. It is exceedingly rare. There are only 24 individuals from 10 families with genetically confirmed Majeed syndrome reported in the literature. The early descriptions of Majeed syndrome reported severely affected children with recurrent fevers, severe multifocal osteomyelitis, failure to thrive, and marked elevations of blood inflammatory markers. As more affected families have been identified, it has become clear that there is significant phenotypic variability. Data supports that disruption of the phosphatidic acid phosphatase activity in LIPIN2 results in immune dysregulation due to aberrant activation of the NLRP3 inflammasome and overproduction of proinflammatory cytokines including IL-1β, however, these findings did not explain the bone phenotype. Recent studies demonstrate that <i>LPIN2</i> deficiency drives pro-inflammatory M2-macrophages and enhances osteoclastogenesis which suggest a critical role of lipin-2 in controlling homeostasis at the growth plate in an inflammasome-independent manner. While there are no approved medications for Majeed syndrome, pharmacologic blockade of the interleukin-1 pathway has been associated with rapid clinical improvement.